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OBJECTIVE—Insulin in pancreatic b-cells is a target of autoim-
munity in type 1 diabetes. In the NOD mouse model of type 1
diabetes, oral or nasal administration of insulin induces immune
tolerance to insulin and protects against autoimmune diabetes.
Evidence for tolerance to mucosally administered insulin or
other autoantigens is poorly documented in humans. Adults with
recent-onset type 1 diabetes in whom the disease process is sub-
acute afford an opportunity to determine whether mucosal insulin
induces tolerance to insulin subsequently injected for treatment.
RESEARCH DESIGN AND METHODS—We randomized 52
adults with recent-onset, noninsulin-requiring type 1 diabetes to
nasal insulin or placebo for 12 months. Fasting blood glucose
and serum C-peptide, glucagon-stimulated serum C-peptide, and
serum antibodies to islet antigens were monitored three times
monthly for 24 months. An enhanced ELISpot assay was used to
measure the T-cell response to human proinsulin.
RESULTS—b-Cell function declined by 35% overall, and 23 of 52
participants (44%) progressed to insulin treatment. Metabolic
parameters remained similar between nasal insulin and placebo
groups, but the insulin antibody response to injected insulin
was signiﬁcantly blunted in a sustained manner in those who
had received nasal insulin. In a small cohort, the interferon-g
response of blood T-cells to proinsulin was suppressed after
nasal insulin.
CONCLUSIONS—Although nasal insulin did not retard loss of
residual b-cell function in adults with established type 1 diabetes,
evidence that it induced immune tolerance to insulin provides
a rationale for its application to prevent diabetes in at-risk indi-
viduals. Diabetes 60:1237–1245, 2011
T
ype 1 diabetes is an autoimmune disease that
destroys insulin-producing b-cells in the islets of
the pancreas. Studies in the NOD mouse model
of spontaneous type 1 diabetes provide compel-
ling evidence that insulin is a prime autoantigen that drives
T-cell–mediated destruction of b-cells (1–3). Insulin is also
a major target of the autoimmune response against b-cells
in children with type 1 diabetes (4,5). Ideally, autoimmune
diseases would be prevented by restoring immune tol-
erance to the autoantigens that are postulated to drive
pathogenic immune responses. In rodent models of auto-
immune disease, exposure of the mucosal immune sys-
tem to soluble autoantigens has been shown to induce
disease-protective immune tolerance associated with
regulatory T-cells (6), for example, in the NOD mouse
after oral (7,8) or aerosol (9) insulin. The potential of
mucosal insulin as an immunotherapeutic agent to prevent
type 1 diabetes in humans would be supported by evidence
that it induces immune tolerance to insulin.
Several studies have examined the effects of mucosal
insulin in type 1 diabetes. Two trials of oral insulin after
the clinical onset of diabetes failed to demonstrate pro-
tection against loss of residual b-cell function (10,11).
These used a very small dose of insulin (7.5-mg daily for 1
year) relative to that which protected NOD mice and did
not document immune responses to oral insulin to dem-
onstrate bioavailability. Moreover, it can be argued that
even if protective immunity had been induced by oral in-
sulin it might be ineffective in clinical, end-stage disease.
The Diabetes Prevention Trial-Type 1 (DPT-1) studied
asymptomatic at-risk, islet autoantibody-positive, ﬁrst-
degree type 1 diabetes relatives (12), using the same low
dose of oral insulin. Although not a prespeciﬁed aim, oral
insulin was found to signiﬁcantly increase disease-free
survival in participants who had circulating autoantibodies
to insulin at entry. Oral insulin is rapidly degraded in the
stomach, and its bioavailability in the upper small intestine
is unpredictable (13). On the other hand, insulin admin-
istered nasally is intact on immediate contact with the
nasopharyngeal mucosa. In asymptomatic children and
young adults with islet autoantibodies at moderate risk for
type 1 diabetes, nasal insulin induced an increase in anti-
body and a decrease in T-cell proliferative responses to
insulin ex vivo (14), consistent with an immune-tolerizing
effect, as observed after aerosol insulin in NOD mice (9).
Subsequently, a randomized trial of nasal insulin adminis-
tered daily to islet autoantibody-positive children less than 3
years of age at very high risk for type 1 diabetes found no
effect on progression to diabetes (15), but evidence for an
effect of nasal insulin on immune function was not reported.
A clear demonstration in humans of immune tolerance
induced by nasal insulin would provide a rationale for
further trials in at-risk individuals selected on the basis of
immune status, disease stage, and risk. Compared with
children with classic type 1 diabetes, adults with type 1
diabetes have greater residual b-cell function at diagnosis
and in many cases do not initially require insulin for
treatment (16). This affords an opportunity to evaluate
whether nasal insulin has a tolerizing effect on immune
responses to insulin subsequently injected for treatment,
analogous to “antigen rechallenge” in animal models. We
therefore conducted a randomized trial to determine the
effect of nasal insulin on immune and metabolic parame-
ters in adults with recent-onset type 1 diabetes.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Participants. Participants were recruited nonselectively from general practice
clinics,communityandhospitaldiabetesclinics,andtheregistryoftheNational
Diabetes Services Scheme (Diabetes Australia). Criteria for inclusion were 1)
diabetes diagnosis in the previous 12 months, based on World Health Orga-
nization criteria (17); 2) age 30–75 years; 3) serum GAD antibody (GADA)
concentration .5 units/mL; 4) fasting serum C-peptide $0.20 nM; 5) stable
blood glucose control (random capillary blood glucose consistently ,10 mmol/L)
with diet and oral hypoglycemic drug therapy; and 6) no previous insulin
injections. Exclusion criteria included previous diabetic ketoacidosis, preg-
nancy or lactation, active malignancy, alcohol or illicit drug dependence, and
chronic liver or renal disease. Fifty-two participants of Caucasian background
provided written informed consent. The study was approved by Melbourne
Health Human Research Ethics Committee.
Protocol. In a double-blind, placebo-controlled trial, participants were com-
puter randomized to nasal insulin and nasal placebo groups by a hospital
pharmacist who remained blinded to the allocation. After instruction, partic-
ipants self-administered treatment via a metered dose nasal spray. Commercial
recombinant human insulin solution (Humulin, 4 mg/mL; Eli Lilly, Indianapolis,
IN)ortheinsulindiluent(placebo)wastransferredundersterileconditionsinto
20-mL brown glass bottles ﬁtted with pump spray nozzles, by the Pharmacy
Department,TheRoyal Melbourne Hospital. Treatment consisted oftwo100 mL
spray doses per nostril, equivalent to a total of 40 units (1.6 mg) insulin, ad-
ministered daily between 7:00 A.M. and 9:00 A.M. for 10 consecutive days and
then on 2 consecutive days weekly for 12 months. The dosing schedule was
based on a previous study (14). Nasal insulin is not absorbed and therefore has
no systemic hormonal or metabolic effects.
Participants were assessed every 3 months for 24 months, by interview,
physical examination, and blood tests for metabolic and immune parameters,
and received advice on diabetes management. The treatment goal was optimal
glycemic control, i.e., fasting blood glucose ,7 mmol/L, postprandial blood
glucose ,10 mmol/L, and HbA1c #7%, based on standard dietary advice and
oral hypoglycemic drugs (metformin, then a sulfonylurea agent). If glycemic
control was suboptimal despite reported adherence to diet and maximal drug
doses, treatment with a mixture of short- and intermediate-acting sub-
cutaneous insulin was instituted. Compliance was assessed from a written
diary and returned spray bottles at each follow-up.
b-Cell function. b-Cell function was assessed by i.v. glucagon-stimulated
secretion of C-peptide (a surrogate for insulin), a validated measure of b-cell
function reasonably comparable to mixed meal test stimulation (18). Partic-
ipants fasted for 10 h overnight, when oral hypoglycemic drugs were withheld.
Blood samples were taken between 8:00 A.M. and 10:00 A.M. via an intravenous
cannula in an antecubital vein. Providing fasting blood glucose was ,10 mmol/L,
blood was collected for serum C-peptide just before (baseline) and 6 min
after 1 mg glucagon i.v. Stimulated C-peptide is the difference between 6 min
and baseline serum concentrations. Serum C-peptide was measured by
chemiluminescence (Immulite 1000; Siemens Healthcare Diagnostics, Deer-
ﬁeld, IL) in all samples from each participant in the one assay. The intra- and
interassay coefﬁcients of variation ranged from 1.5 to 3.7 and 9.4 to 10.0%,
respectively.
Islet autoantibodies. GADA and antibodies to tyrosine phosphatase-like
insulinoma-associated protein2antigen (IA2A) were measuredbyprecipitation
of in vitro transcribed-translated GAD65 or IA2 biosynthetically labeled with
[
35S]methionine. Speciﬁcity and sensitivity in the Diabetes Autoantibody
Standardization Program (19) were 76 and 94% for GADA and 72 and 100% for
IA2A, respectively. Insulin autoantibodies (IAAs), or insulin antibodies (IAs)
induced by treatment with subcutaneous insulin injections were measured by
precipitation of
125I-(A14) human insulin (20). Speciﬁcity and sensitivity of the
IAA assay in the Diabetes Autoantibody Standardization Program were 99 and
22%, respectively. The thresholds for GADA, IA2A, and IAA/IA positivity, 5, 3,
and 1.0 units/mL, respectively, were established as the 97.5 percentiles of
unselected healthy children and young adults.
Proinsulin-speciﬁc T-cells. Tetanus toxoid was provided by CSL (Parkville,
Victoria, Australia). Recombinant human proinsulin was produced as pre-
viously described (21). After refolding and puriﬁcation by reversed-phase high-
performance liquid chromatography, the protein was resolved as a single
species of expected molecular mass by matrix-assisted laser desorption/
ionization-time of ﬂight mass spectrometry. The endotoxin concentration of
proinsulin stock solution used was 0.51 EU/mg/mL. The response of T-cells to
tetanus toxoid and human proinsulin was measured in an interferon (IFN)-g
ELISpot assay (22), the sensitivity of which was enhanced by incorporating
agents to promote antigen-presenting cell function. Peripheral blood mono-
nuclear cells (PBMCs) were prepared by Ficoll gradient centrifugation from
ﬁve participants in each group, at baseline and 3 months, and stored over
liquid nitrogen in 10% fetal calf serum/90% DMSO. Cells were rapidly thawed at
37°C, diluted in AIM-V serum-free medium (Invitrogen Australia, Mulgrave,
Victoria, Australia), tested for viability by trypan blue (0.2%) exclusion and
counted. PBMCs were then plated at 2.5 3 10
6 cells/250 mL/well in 48-well
plates in AIM-V medium supplemented with granulocyte macrophage colony-
stimulating factor (1,000 units/mL) and interleukin-4 (500 units/mL) (Preprotec,
Rocky Hill, NJ) and containing tetanus toxoid (10 Lyons ﬂocculating units
[LfU]/mL), proinsulin (9 mg/mL), or no antigen. After 24 h (day 1), anti-CD40
monoclonal antibody (10 mg/mL; clone G28.5, produced in-house), IFN-a (1,000
units/mL) (Roferon-A; Roche, Dee Why, Australia), and interleukin-7 (0.5 ng/
mL) (Preprotec) were added. On day 2, nonadherent cells were collected,
washed, and resuspended in fresh AIM-V medium, counted, and 3 3 10
5
transferred in triplicate to wells of an ELISpot plate. The plate was incubated
for 6 h at 37°C and processed for IFN-g spots as described (22). Spots were
counted electronically (AID Autoimmun Diagnostika, Strassberg, Germany),
and medians of replicates were determined, subtracted for no antigen back-
ground, and expressed as spots/10
6 cells.
HLA. Class II HLA-DR typing was performed by PCR-based sequence-speciﬁc
oligonucleotide hybridization based on the 11th International Histocompati-
bility Workshop protocols (23) with minor modiﬁcation to accommodate se-
quence polymorphisms subsequently described (24).
Statistical analysis. Primary end points were stimulated serum C-peptide and
the IA response to subcutaneous insulin. After diagnosis, glucagon-stimulated
C-peptide in adults with type 1 diabetes is reported to decline by 20% per year,
as reviewed by Fourlanos et al. (16). The sample size required to determine
whether treatment would halve this decline, with a power of 80% in a two-
sided test at a 5% level of signiﬁcance, was estimated to be 21 per group. There
were no previous data to estimate power for an effect of nasal insulin on the
IA response to subcutaneous insulin.
Differences in continuous variables (C-peptide, fasting glucose, HbA1c, and
IA concentrations) between baseline and 3-month time points were analyzed
by nonparametric Mann-Whitney tests or paired t tests. Differences in cate-
goric values (sex and HLA status) were analyzed by contingency Fisher exact
test. The log-rank test was used to analyze Kaplan-Meier survival curves for
progression to subcutaneous insulin treatment in the two trial arms. Correlation
was analyzed by the Spearman rank test. Statistical analyses were performed
with GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA).
RESULTS
Characteristics of participants in the nasal insulin and
placebo arms did not differ at baseline (Table 1). Blood
glucose control (median HbA1c 6.6%) was satisfactory
overall, but participants were overweight (median BMI
27.0 kg/m
2). All had GADA, 16 of 52 (31%) had IA2A, and
ﬁve of 52 (10%) had IAA. These have all been deﬁned
above. HLA class II DR 3 or 4 risk alleles for type 1 di-
abetes were present in 47 of 52 participants (90%).
Metabolic parameters. Glucagon-stimulated serum C-
peptide, a measure of b-cell function, decreased overall by
35% over 24 months, from a baseline median of 0.43 nmol/L
[interquartile range 0.24–0.62] to a median of 0.28 nmol/L
[0.06–0.49] (P = 0.012). Likewise, fasting serum C-peptide
decreased by 33% from a baseline median of 0.75 nmol/L
[0.48–0.98] to 0.50 nmol/L [0.23–0.95] (P = 0.043). The de-
cline in b-cell function did not differ between the nasal
insulin and placebo groups (Fig. 1A and B). At 24 months,
median stimulated serum C-peptide in the nasal insulin
group was 0.27 [0.06–0.60] nM compared with 0.29 [0.06–
0.48] nM in the placebo group (P = 0.86). The change in
b-cell function was also assessed from the slopes of
stimulated serum C-peptide during the study (nasal insulin
–0.011 vs. nasal placebo –0.018; P = 0.99), conﬁrming there
was no difference between the nasal insulin and placebo
groups.
Blood glucose control did not change over the course of
the study; median HbA1c at baseline was 6.6% [5.8–7.6]
compared with 6.9% [6.3–7.6] at 24 months (P = 0.64,
Kruskal-Wallis test). Fasting plasma glucose and HbA1c did
not differ between the nasal insulin and nasal placebo
groups (Fig. 1C and D). Glycemia control was attribut-
able to close monitoring and prompt escalation of oral
hypoglycemic drugs or rapid transition to treatment with
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to insulin treatment over 24 months occurred in 23 of 52
participants (44%), being similar in the nasal insulin (12/26)
and placebo (11/26) groups (log-rank test P = 0.88; Fig. 2A).
Immune parameters. Concentrations of GADA and IA2A
were similar at baseline in the nasal insulin and placebo
groups and remained unchanged throughout the study
(Fig. 1E and F). At baseline, only three participants in the
nasal insulin group and two participants in the control
group had detectable IAA (Table 2). After treatment with
subcutaneous insulin, the induced IA response (Table 2)
was signiﬁcantly blunted in participants who had received
nasal insulin. This is illustrated in several ways (Figs. 2 and
3). First, IA concentration is plotted for each participant in
the nasal placebo (Fig. 2B) or nasal insulin (Fig. 2C) group
at 3-month intervals and as the medians of the two groups
at 3-month intervals (Fig. 2D). Second, because not all
participants progressed to subcutaneous insulin and those
who did commenced treatment at different times in the
study, IA concentration is plotted by time after com-
mencing subcutaneous insulin (Fig. 2E). In addition, IA
concentration is plotted as the absolute change from pre-
treatment baseline at 3, 6, 9, and 12 months after com-
mencing subcutaneous insulin (Fig. 3). From areas under
the curves (Fig. 2D), IA concentration was signiﬁcantly
lower in those from the nasal insulin group than the
placebo group (4.1 vs. 12.2 units/mL, P = 0.001). By 24
months, IA concentration in participants receiving sub-
cutaneous insulin was signiﬁcantly lower in the 12 who
had received nasal insulin (4.7 [2.3–11] units/mL) than in
the 11 who had received nasal placebo (17 [6.0–32] units/
mL) (P = 0.019) (Fig. 2E). The IA concentration in partic-
ipants who had received nasal insulin remained sup-
pressed to at least 12 months after commencing daily
subcutaneous insulin treatment (Fig. 3). The relationship
between subcutaneous insulin dose (shown in Table 2 as
total daily dose) and the IA response was examined. The
median dose of subcutaneous insulin in the nasal insulin
group (26 units; [interquartile range 20–34]) was not sig-
niﬁcantly different from that in the placebo group (34
units; interquartile range 22–50) (P = 0.34). In the nasal
insulin group only, insulin dose and IA concentration were
signiﬁcantly correlated at 3 months (r = 0.81, P = 0.001)
and 6 months (r = 0.64, P = 0.024) after starting sub-
cutaneous insulin, but in each case signiﬁcance depended
on the single highest paired values. Time to the start of
subcutaneous insulin or HLA DR allele status did not differ
signiﬁcantly between the groups.
IFN-g ELISpot responses to proinsulin and a control
antigen, tetanus toxoid, were measured on frozen-thawed
PBMCs available from ﬁve participants in each group at
baseline and 3 months (Fig. 4). No participant required
TABLE 1
Baseline characteristics of participants
Characteristic Nasal insulin (n = 26) Nasal placebo (n = 26) P value
Age (years) 48.4 [40.3–51.5]* 45.6 [38.3–55.1] 0.71
Male 12 14
Female 14 12 0.78†
BMI 26.4 [24.0–31.9] 27.3 [24.9–31.6] 0.82
Waist circumference (cm) 95 [88–108] 97 [90–103] 0.77
Waist-hip ratio 0.93 [0.88–0.98] 0.90 [0.85–0.95] 0.33
Treatment at randomization
Diet alone 6 4 0.80‡
Metformin alone 5 9
Sulphonylurea alone 7 7
Metformin and sulphonylurea 8 6
Blood HbA1c (%) 6.7 [5.9–7.6] 6.6 [5.9–7.7] 0.91
Fasting serum lipids (mmol/L)
Total cholesterol 4.5 [4.0–5.6] 4.5 [4.1–5.3] 0.87
Triglycerides 1.2 [0.8–1.9] 1.5 [0.9–1.8] 0.39
HDL cholesterol 1.1 [1.0–1.4] 1.1 [1.0–1.3] 0.52
LDL cholesterol 2.7 [2.2–3.5] 2.4 [2.3–3.4] 0.89
Fasting plasma glucose (mmol/L) 7.1 [5.8–8.0] 6.7 [6.0–7.8] 0.99
Fasting serum C-peptide (nM) 0.70 [0.43–1.00] 0.75 [0.59–0.95] 0.58
Stimulated serum C-peptide (nM) 0.50 [0.28–0.71] 0.37 [0.25–0.54] 0.29
Serum GADA
n 26 26 1.0
Concentration (units/mL) 61 [29–76] 56 [24–78] 0.80
Serum IA2A
n 6 10 0.25
Concentration (units/mL) 20.5 [20.9 to 1.5] 0.0 [21.0 to 17] 0.76
Serum IAA
n 2 2 1.0
Concentration (units/mL) 0.2 [0.0–0.4] 0.3 [0.1–0.5] 0.11
HLA DR risk alleles
Combinations of DR3 and DR4 14 15 0.68‡
Either DR3 or DR4 9 9
Neither DR3 nor DR4 3 2
*Values expressed as median [interquartile range]. †x
2 test. ‡x
2 test for trend.
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toxoid were similar between the groups at baseline and 3
months. However, responses to proinsulin decreased
signiﬁcantly by 3 months in participants who received
nasal insulin (P = 0.03; paired, one-tailed t test) but not
placebo (P =0 . 3 1 ) .
DISCUSSION
Mucosa-mediated immune tolerance in humans was ﬁrst
demonstrated to the experimental antigen, keyhole limpit
hemocyanin (KLH), given orally (25) or nasally (26) to
healthy volunteers. After oral KLH, T-cell but not B-cell
(antibody) responses to rechallenge with subcutaneous
FIG. 1. Trial outcomes: stimulated serum C-peptide (A), fasting serum C-peptide (B), blood HbA1c (C), fasting plasma glucose (D), serum GADA
(E), and serum IA2A (F). Median values for the nasal insulin and nasal placebo groups are indicated by closed and open symbols, respectively.
Interquartile ranges are shown as vertical lines.
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responses to subcutaneous KLH were suppressed, sug-
gesting that tolerance induction via the nasal route may be
more effective. Despite these ﬁndings, and a wealth of
evidence for tolerogenic protective effects of oral or nasal
autoantigen in mouse models of autoimmune disease,
reviewed by Harrison and Haﬂer (6), the therapeutic prom-
ise of mucosa-mediated tolerance for human autoimmune
FIG. 2. A: Progression to treatment with subcutaneous (s.c.) insulin, plotted as Kaplan-Meier survival curves (nasal insulin participants, solid line;
nasal placebo participants, dashed line). B: IA concentrations in nasal placebo participants at 3-month study intervals. C: IA concentrations in
nasal insulin participants at 3-month study intervals. D: Median IA concentrations for all participants at 3-month study intervals (includes values
before and after commencement of subcutaneous insulin). ○, Nasal placebo and ●, nasal insulin participants. Upper quartile ranges (divided by 5
to allow ﬁt) are shown as vertical lines. E: Median IA concentrations in nasal placebo (○) and nasal insulin (●) participants by time after
commencement of subcutaneous insulin. Upper quartile ranges are shown as vertical lines.
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planation may be that earlier human studies were con-
ducted in advanced disease. In addition, evidence that
administered autoantigen was bioavailable and elicited
immune responses consistent with tolerance has been
lacking. Our ﬁnding that the antibody response to sub-
cutaneous insulin was suppressed by prior treatment with
nasal insulin is the ﬁrst evidence for immune tolerance
TABLE 2
Insulin antibody concentrations (units/milliliters) in trial participants
Participant Baseline
Months in trial Days of s.c. insulin
before measurement
of IA 3.0 6.0 9.0 12 15 18 21 24
Nasal insulin
1 0.6 0.0 0.5 0.2 0 0 0 0 0
2 0.0 0.0 0.0 0.0 2.4 (13)* 1.8 (13) 3.0 (12) 1.9 (11) 1.0 (11) 90
3 0.0 0.6 0.6 0.0 0.4 0.2 0.0 0.3 0.3
4 0.6 0.8 0.0 1.1 0.4 0.0 0.4 0.4 0.3
5 0.0 0.0 0.4 0.2 (10) 0.0 (12) 0.5 (15) 1.0 (14) 1.7 (16) 1.4 (17) 35
6 0.4 0.4 0.3 0.4 (16) 0.4 (18) 1.4 (31) 5.1 (36) 5.6 (32) 5.2 (33) 75
7 0.0 0.0 0.0 0.0 0.2 0.0 0.0 1.4 (24) 21.0 (31) 90
8 0.0 0.0 0.0 0.5 0.0 0.0 0.3 (12) 0.8 (24) 4.1 (46) 30
9 0.5 3.3 2.3 3.3 (10) 9.3 (21) 16.0 (22) 19.0 (21) 37.0 (24) 26.0 (26) 75
10 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0
11 0.0 0.0 0.4 0.0 0.0 0.6 0.0 0.0 0.0
12 0.0 0.5 NA 2.5 (50) 2.1 (67) NA (67) 1.3 (63) 1.6 (49) 1.0 (48) 90
13 0.2 0.0 0.4 0.0 0.5 0.0 0.0 0.0 0.3
14 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.4 0.0
15 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0
16 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1
17 6.9 2.8 4.1 3.1 2.8 2.2 7.1 (30) 5.0 (34) 7.4 (36) 90
18 0.3 0.6 0.4 0.0 0.3 0.3 0.0 0.1 0.2
19 0.4 0.1 0.0 0.3 0.5 0.0 0.2 0.0 0.0
20 0.0 NA 0.4 0.0 0.3 0.0 0.0 0.0 0.5
21 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.5 (36) 2.6 (32) 90
22 5.5 0.4 0.9 0.4 0.5 0.5 0.4 2.3 (18) 5.8 (23) 90
23 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6
24 0.0 0.0 0.0 0.3 0.5 0.0 NA 2.4 (26) 3.1 (20) 90
25 2.9 3.1 3.1 34.0 (74) 28.0 (92) 17.0 (98) 18.0 (110) NA (114) 35.0 (124) 90
26 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0
Nasal placebo
27 0.4 0.0 28.0 (30) 85.0 (42) 68.0 (44) 94.0 (50) 38.0 (50) 67.0 (55) 44.0 (57) 20
28 0.9 0.9 0.5 6.0 0.4 0.1 0.3 0.8 0.3
29 1.4 2.0 1.0 2.5 2.0 2.6 2.0 1.1 2.2
30 0.0 0.0 0.3 0.0 0.7 0.2 0.0 0.0 0.0
31 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0
32 0.4 0.0 0.0 0.0 0.0 0.3 0.6 0.0 0.2
33 0.0 0.6 0.3 0.6 0.0 0.3 0.5 2.2 0.5
34 0.4 0.7 1.4 0.8 1.2 1.2 1.9 1.0 1.2
35 0.6 0.3 0.0 0.5 0.5 0.4 0.3 0.0 7.6 (22) 11
36 0.6 0.5 0.2 0.5 0.0 0.4 0.4 3.3 (36) 8.6 (32) 30
37 0.5 0.0 0.4 0.2 0.3 0.0 0.3 0.0 0.2
38 0.3 0.3 0.2 0.3 0.2 0.3 0.7 0.6 0.5
39 0.4 0.0 0.4 0.3 0.7 3.3 (10) 7.0 (20) 4.8 (32) 4.6 (35) 14
40 0.0 0.4 0.0 0.3 0.0 1.5 1.8 (14) 11.0 (22) 17.0 (29) 75
41 0.3 0.5 0.6 9.9 (40) 9.2 (40) 11.0 (30) 100.0 (54) 50.0 (64) 35.0 (74) 75
42 1.0 0.5 21.0 (42) 18.0 (50) 17.0 (55) 13.0 (54) 19.0 (54) 12.0 (53) 32.0 (57) 20
43 13.0 4.6 3.7 3.4 5.0 5.2 NA 5.6 (70) 22.0 (82) 90
44 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.3 0.0
45 0.1 0.4 0.4 0.3 0.3 0.4 0.1 0.0 0.3
46 0.0 0.0 0.1 0.0 0.5 0.3 0.3 0.0 0.0
47 0.4 0.5 1.4 0.8 0.0 0.2 0.6 (58) 6.7 (46) 6.1 (46) 42
48 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.3
49 0.0 0.0 0.0 1.8 (10) 30.0 (18) 94.0 (20) 50.0 (18) 47.0 (20) 32.0 (24) 75
50 0.8 0.4 0.0 0.6 5.0 0.0 0.2 0.0 0.1
51 0.7 0.0 0.4 0.4 0.6 2.0 0.4 0.3 0.4
52 0.4 0.3 0.3 3.1 (24) 4.4 (34) 4.6 (26) 6.2 (26) 9.5 (30) 6.1 (34) 90
Treatment with subcutaneous insulin is indicated in boldface, and total daily insulin dose is shown in parentheses. *Subcutaneous insulin dose
(units). NA, not assayed; s.c., subcutaneous.
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in humans. Tolerance was robust because the suppressive
effect was sustained in the majority of individuals despite
ongoing daily insulin injections. Differences between the
nasal insulin and placebo groups could not be attributed to
the doses of subcutaneous insulin required. Tolerance to
exogenous insulin does not necessarily equate with toler-
ance to endogenous insulin, i.e., with suppression of auto-
immune responses to insulin. This is implied, however, by
evidence for tolerance at the T-cell level, namely, suppres-
sion of IFN-g responses to proinsulin after nasal insulin in
a small cohort, which must be qualiﬁed by the lack of T-cell
data across the study. Proinsulin rather than insulin was
used for the ELISpot assay because the serum-free medium
contained insulin, but T-cells recognize epitopes in pro-
insulin that are not present in insulin (1,27).
There are several possible reasons why immune toler-
ance to insulin induced by nasal insulin might not have
translated into suppression of immunity to other islet
autoantigens or protection against ongoing loss of b-cell
function in adults with type 1 diabetes. First, on the basis
of the prevalence of autoantibodies, insulin does not seem
to be a major autoantigen in this population (16), and
protection may require induction of tolerance to other islet
autoantigens. On the other hand, although the mechanism
of nasal insulin–induced tolerance in humans remains to
be deﬁned, studies in mice (6) show that regulatory T-cells
induced by mucosal administration of a single autoantigen
can have a bystander effect to suppress T-cell responses to
other autoantigens presented in the same microenviron-
ment, e.g., pancreas draining lymph nodes. T-cell responses
to GAD were suppressed by aerosol insulin in the NOD
mouse (9), but evidence is lacking that bystander suppres-
sion induced by one antigen modiﬁes ongoing antibody
responses to other autoantigens. Irrespective whether T-cell
tolerance involves induction of insulin-speciﬁcr e g u l a t o r y
T-cells or the deletion or anergy of insulin-speciﬁc patho-
genic T-cells, the outcome may be impaired T-cell “help” for
IA production by B-cells. Techniques for reliably identifying
and characterizing autoantigen-speciﬁc T-cells in human
FIG. 3. Changes in IA concentration from baseline at 3, 6, 9, and 12 months after commencing subcutaneous insulin in nasal placebo (○) and nasal
insulin (●) participants. Medians (horizontal lines) and quartile ranges (vertical lines) are shown. IA measurements made within 30 days of
commencing subcutaneous insulin were not considered.
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their application. Second, b-cell function declined by more
than 30% over 24 months with more than 40% of participants
becoming insulin-dependent, indicating progressive loss of
b-cell function to end-stage disease. Trials of oral insulin in
adults with recent-onset type 1 diabetes (10,11), while not
documenting immune outcomes, also found no effect on
residual b-cell function. If the balance between pathogenic
and protective immunity determines clinical outcome, then
autoantigen-speciﬁc vaccination should be most effective
before or soon after the onset of subclinical disease. Indeed,
studies in animal models show no evidence that this ap-
proach is protective by the time clinical disease ensues.
Third, it is possible that immune tolerance to insulin, even if
induced early in the disease process, may be protective only
in individuals with preexisting autoimmunity to insulin, as
seen in the DPT-1 oral insulin trial (12). Finally, although
administration of nasal insulin was associated with suppres-
sion of the antibody response to injected insulin, destruction
of b-cells is primarily T-cell mediated. Further studies are
required not only to determine whether nasal insulin induces
insulin-speciﬁc regulatory T-cells but also to conﬁrm that,
like nasal KLH (26), nasal insulin induces changes in T-cell
function to rechallenge indicative of T-cell tolerance.
An important question is whether insulin-induced toler-
ance would be protective in islet autoantibody-positive
children at risk for type 1 diabetes in whom, in contrast
with adults with type 1 diabetes, insulin seems to be
a major autoantigen (4,5). In the DPT-1 randomized con-
trolled trial of oral insulin (12), participating relatives with
type 1 diabetes at entry had an interquartile age of 7–14
years and normal b-cell function. Notably, treatment with
oral insulin was associated with slower progression to
diabetes in the slightly younger IAA-positive cohort. In the
type 1 diabetes Prediction and Prevention Project ran-
domized trial in Finland (15), nasal insulin had no effect on
progression to diabetes in islet autoantibody-positive
children less than 3 years of age. Such children are a very
high-risk group, and many had low ﬁrst-phase insulin re-
sponse to intravenous glucose. Given end-stage b-cell func-
tion, they would be less likely to exhibit a clinical response.
Again, immune tolerance to insulin was not documented in
either trial of oral or nasal insulin in at-risk individuals. A
proposed trial (Pre-POINT) (28) aims to address questions
of optimal timing, disease stage, dose, and route of admin-
istration by intervening with oral or nasal insulin in children
genetically predisposed to type 1 diabetes before the ap-
pearance of islet autoantibodies. The evidence demon-
strated here for nasal insulin–induced immune tolerance
provides a mechanistic rationale for studies that aim to re-
store immune tolerance before the development of islet
pathology.
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